SAB Biotherapeutics Inc. (SABS)
SAB Biotherapeutics Statistics
Share Statistics
SAB Biotherapeutics has 9.29M shares outstanding. The number of shares has increased by 0% in one year.
Shares Outstanding | 9.29M |
Shares Change (YoY) | 0% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 5.11% |
Shares Floating | 7.49M |
Failed to Deliver (FTD) Shares | 6.83K |
FTD / Avg. Volume | 6% |
Short Selling Information
The latest short interest is 53.47K, so 0.58% of the outstanding shares have been sold short.
Short Interest | 53.47K |
Short % of Shares Out | 0.58% |
Short % of Float | 0.72% |
Short Ratio (days to cover) | 0.78 |
Valuation Ratios
The PE ratio is -1.03 and the forward PE ratio is -0.44. SAB Biotherapeutics's PEG ratio is 0.02.
PE Ratio | -1.03 |
Forward PE | -0.44 |
PS Ratio | 26.54 |
Forward PS | 0.1 |
PB Ratio | 1.35 |
P/FCF Ratio | -1.02 |
PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for SAB Biotherapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.98, with a Debt / Equity ratio of 0.18.
Current Ratio | 2.98 |
Quick Ratio | 2.98 |
Debt / Equity | 0.18 |
Debt / EBITDA | -0.11 |
Debt / FCF | -0.14 |
Interest Coverage | 134.77 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $23.2K |
Profits Per Employee | $-598.34K |
Employee Count | 57 |
Asset Turnover | 0.03 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -71.52% in the last 52 weeks. The beta is 0.45, so SAB Biotherapeutics's price volatility has been higher than the market average.
Beta | 0.45 |
52-Week Price Change | -71.52% |
50-Day Moving Average | 1.92 |
200-Day Moving Average | 2.78 |
Relative Strength Index (RSI) | 31.17 |
Average Volume (20 Days) | 113.96K |
Income Statement
In the last 12 months, SAB Biotherapeutics had revenue of 1.32M and earned -34.11M in profits. Earnings per share was -3.68.
Revenue | 1.32M |
Gross Profit | 1.32M |
Operating Income | -42.91M |
Net Income | -34.11M |
EBITDA | -42.91M |
EBIT | -34.42M |
Earnings Per Share (EPS) | -3.68 |
Balance Sheet
The company has 8.9M in cash and 4.67M in debt, giving a net cash position of 4.23M.
Cash & Cash Equivalents | 8.9M |
Total Debt | 4.67M |
Net Cash | 4.23M |
Retained Earnings | -124.17M |
Total Assets | 44.2M |
Working Capital | 15.81M |
Cash Flow
In the last 12 months, operating cash flow was -34.29M and capital expenditures 0, giving a free cash flow of -34.29M.
Operating Cash Flow | -34.29M |
Capital Expenditures | 0 |
Free Cash Flow | -34.29M |
FCF Per Share | -3.7 |
Margins
Gross margin is 100%, with operating and profit margins of -3244.87% and -2579.03%.
Gross Margin | 100% |
Operating Margin | -3244.87% |
Pretax Margin | -2579.03% |
Profit Margin | -2579.03% |
EBITDA Margin | -3244.87% |
EBIT Margin | -3244.87% |
FCF Margin | -2593.15% |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for SABS is $9.5, which is 648% higher than the current price. The consensus rating is "Buy".
Price Target | $9.5 |
Price Target Difference | 648% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Stock Splits
The last stock split was on Jan 5, 2024. It was a backward split with a ratio of 1:10.
Last Split Date | Jan 5, 2024 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | -5.65 |
Piotroski F-Score | 2 |